This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| In Vitro Diagnostic Regulation | |
|---|---|
| Name | In Vitro Diagnostic Regulation |
| Jurisdiction | European Union |
| Status | Active |
| Enacted | 2017 |
| Commenced | 2022 |
| Related legislation | Medical Device Regulation (EU) 2017/745, Directive 98/79/EC |
In Vitro Diagnostic Regulation The In Vitro Diagnostic Regulation (IVDR) is a legislative framework governing in vitro diagnostics within the European Union that replaced Directive 98/79/EC and introduced new requirements for conformity, performance, and post-market surveillance. It affects manufacturers, notified bodies, clinical laboratories, and competent authorities across member states such as Germany, France, Italy, Spain, and Poland. The IVDR intersects with international instruments and actors including the World Health Organization, International Organization for Standardization, and European Medicines Agency.
The IVDR was adopted by the European Parliament and the Council of the European Union following negotiations involving stakeholders like European Commission, MedTech Europe, European Centre for Disease Prevention and Control, and national regulators in Netherlands, Sweden, and Belgium. Its scope extends to specialist tests used in University Hospital of Geneva-style reference settings and commercial assays produced by firms such as Roche, Siemens Healthineers, Abbott Laboratories, Thermo Fisher Scientific, and Becton Dickinson. The regulation introduced new device classification and requirements affecting notified bodies such as TÜV SÜD, BSI Group, DEKRA, and LNE-GMED.
Within the European Union, the IVDR harmonizes requirements enforced by national competent authorities like German Federal Institute for Drugs and Medical Devices, Agence nationale de sécurité du médicament et des produits de santé, and Agenzia Italiana del Farmaco. Outside the EU, jurisdictions have analogous frameworks: the United States Food and Drug Administration regulates IVDs under the Food, Drug, and Cosmetic Act, while Health Canada applies its Medical Devices Regulations, and Therapeutic Goods Administration oversees devices in Australia. International bodies such as European Committee for Standardization, International Medical Device Regulators Forum, and Council of the European Union inform cross-border convergence affecting companies like BioMérieux, Qiagen, Danaher Corporation, and Johnson & Johnson.
The IVDR introduced risk-based classification rules similar to approaches in United States Food and Drug Administration guidances and influenced by standards from International Organization for Standardization and European Committee for Standardization. Devices are classified into classes A through D with high-risk assays (e.g., companion diagnostics) requiring involvement of European Medicines Agency pathways and notified bodies such as BSI Group for conformity assessment. Manufacturers must demonstrate compliance with standards like ISO 13485, ISO 14971, and harmonized specifications developed in coordination with agencies including Paul Ehrlich Institute and Swedish Medical Products Agency.
IVDR mandates active post-market surveillance systems paralleling frameworks used by European Centre for Disease Prevention and Control and reporting obligations to databases akin to Eudamed. Vigilance responsibilities align with practices at organizations like Robert Koch Institute and Public Health England and require coordination with national authorities such as Spanish Agency of Medicines and Medical Devices and Finnish Medicines Agency. Serious incident reporting workflows refer to models used by United States Food and Drug Administration's MedWatch and international cooperation via forums like International Medical Device Regulators Forum.
Under IVDR, clinical performance studies and scientific validity are assessed using methodologies comparable to those applied by European Medicines Agency, National Institutes of Health, and consortia such as European Network for Health Technology Assessment. Manufacturers must produce performance evaluation reports akin to submissions to Food and Drug Administration for devices from firms including Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, and academic developers from institutions like Karolinska Institutet and Charité – Universitätsmedizin Berlin. Ethics review processes often involve bodies such as National Research Ethics Service and Comité de Protection des Personnes.
The IVDR prescribes labeling, instructions for use, and Unique Device Identification (UDI) requirements interoperable with systems used by United States Food and Drug Administration and global UDI initiatives coordinated by World Health Organization. Information must be accessible to stakeholders including clinicians at Mayo Clinic, Cleveland Clinic, and laboratory networks like EuroLab and European Federation of Clinical Chemistry and Laboratory Medicine. Economic actors such as Medtronic and procurement bodies like European Investment Bank are affected by traceability and transparency provisions.
Implementation of IVDR posed challenges reminiscent of regulatory transitions overseen by European Medicines Agency and World Health Organization during device reforms, impacting small and medium enterprises represented by associations such as MedTech Europe and European Association of Medical Devices Notified Bodies. Key issues include notified body capacity seen in disputes involving TÜV SÜD and BSI Group, supply-chain impacts for multinational corporations like Johnson & Johnson and Danaher Corporation, and research translation concerns for academic centers including University of Oxford, University of Cambridge, Imperial College London, and Heidelberg University Hospital. The regulation has catalyzed dialogue among policymakers in European Commission, industry groups like European Federation of Pharmaceutical Industries and Associations, and public health organizations such as World Health Organization.
Category:European Union medical device law